Morgan Stanley’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-90
| Closed | -$176 | – | 8140 |
|
|
2023
Q4 | $176 | Buy |
90
+45
| +100% | +$91 | ﹤0.01% | 7362 |
|
|
2023
Q3 | $108 | Hold |
45
| – | – | ﹤0.01% | 7438 |
|
|
2023
Q2 | $133 | Sell |
45
-1
| -2% | -$5 | ﹤0.01% | 7480 |
|
|
2023
Q1 | $515 | Sell |
46
-1
| -2% | -$13 | ﹤0.01% | 7434 |
|
|
2022
Q4 | $533 | Sell |
47
-43
| -48% | -$500 | ﹤0.01% | 7551 |
|
|
2022
Q3 | $1K | Buy |
90
+50
| +125% | +$1.23K | ﹤0.01% | 7651 |
|
|
2022
Q2 | $2K | Buy |
40
+14
| +54% | +$2.03K | ﹤0.01% | 7631 |
|
|
2022
Q1 | $10K | Sell |
26
-14
| -35% | -$8.94K | ﹤0.01% | 7415 |
|
|
2021
Q4 | $39K | Sell |
40
-220
| -85% | -$310K | ﹤0.01% | 6928 |
|
|
2021
Q3 | $500K | Sell |
260
-125
| -32% | -$283K | ﹤0.01% | 5499 |
|
|
2021
Q2 | $1.02M | Buy |
385
+374
| +3,400% | +$1.23M | ﹤0.01% | 5061 |
|
|
2021
Q1 | $47K | Sell |
11
-25
| -69% | -$135K | ﹤0.01% | 6380 |
|
|
2020
Q4 | $206K | Buy |
36
+21
| +140% | +$124K | ﹤0.01% | 5573 |
|
|
2020
Q3 | $93K | Sell |
15
-4
| -21% | -$22.9K | ﹤0.01% | 5461 |
|
|
2020
Q2 | $103K | Buy |
19
+17
| +850% | +$88.3K | ﹤0.01% | 5389 |
|
|
2020
Q1 | $6K | Buy |
2
+1
| +100% | +$5.74K | ﹤0.01% | 6168 |
|
|
2019
Q4 | $7K | Buy |
+1
| New | +$3.49K | ﹤0.01% | 6356 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6829 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6812 |
|
|
2019
Q1 | – | Sell |
-6
| Closed | -$12.7K | – | 6770 |
|
|
2018
Q4 | $7K | Sell |
6
-4
| -40% | -$6.13K | ﹤0.01% | 6251 |
|
|
2018
Q3 | $8K | Sell |
10
-7
| -41% | -$5.13K | ﹤0.01% | 6357 |
|
|
2018
Q2 | $17K | Sell |
17
-19
| -53% | -$66.7K | ﹤0.01% | 6189 |
|
|
2018
Q1 | $185K | Sell |
36
-18
| -33% | -$119K | ﹤0.01% | 5504 |
|
|
2017
Q4 | $289K | Buy |
54
+10
| +23% | +$93.1K | ﹤0.01% | 5268 |
|
|
2017
Q3 | $389K | Buy |
44
+42
| +2,100% | +$323K | ﹤0.01% | 5023 |
|
|
2017
Q2 | $11K | Sell |
2
-8
| -80% | -$55.4K | ﹤0.01% | 6225 |
|
|
2017
Q1 | $62K | Sell |
10
-11
| -52% | -$55.3K | ﹤0.01% | 5771 |
|
|
2016
Q4 | $238K | Buy |
21
+17
| +425% | +$238K | ﹤0.01% | 5285 |
|
|
2016
Q3 | $55K | Buy |
4
+2
| +100% | +$28.5K | ﹤0.01% | 5550 |
|
|
2016
Q2 | $24K | Hold |
2
| – | – | ﹤0.01% | 5792 |
|
|
2016
Q1 | $29K | Hold |
2
| – | – | ﹤0.01% | 5812 |
|
|
2015
Q4 | $47K | Sell |
2
-2
| -50% | -$31.6K | ﹤0.01% | 5743 |
|
|
2015
Q3 | $53K | Sell |
4
-8
| -67% | -$142K | ﹤0.01% | 5703 |
|
|
2015
Q2 | $200K | Sell |
12
-6
| -33% | -$128K | ﹤0.01% | 5230 |
|
|
2015
Q1 | $325K | Buy |
+18
| New | +$315K | ﹤0.01% | 4933 |
|
|
2014
Q4 | – | Hold |
0
| – | -$4K | – | 6707 |
|
|
2014
Q3 | – | Sell |
-15
| Closed | -$232K | – | 6371 |
|
|
2014
Q2 | $262K | Buy |
+15
| New | +$217K | ﹤0.01% | 5024 |
|
Other funds holding AGRX
Morgan Stanley's AGRX Position: Q1 2024 in Review
Morgan Stanley sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 90 shares — an estimated $176 sold.
Morgan Stanley first reported a position in AGRX in Q2 2014 and held it in 34 quarters. The position peaked at $1.02M in Q2 2021. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- Morgan Stanley reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- Morgan Stanley sold 90 Agile Therapeutics shares in Q1 2024, an estimated $176.
- Morgan Stanley first reported a position in Agile Therapeutics in Q2 2014 and held it in 34 quarters.
- Morgan Stanley's Agile Therapeutics position peaked at $1.02M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.